Trial Profile
Phase I Study of the Combination of Afatinib and Ruxolitinib in Patients With Treatment-refractory Non-Small Cell Lung Cancer (NSCLC)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Afatinib (Primary) ; Ruxolitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 27 Mar 2019 Status changed from recruiting to completed.
- 18 Oct 2017 Updated analysis results (n=21) assessing safety and efficacy of the combination of afatinib and ruxolitinib in NSCLC patients who had progressed on EGFR-TKIs, were presented at the 18th World Conference on Lung Cancer.
- 18 Oct 2017 Status changed from planning to recruiting, according to results presented at the 18th World Conference on Lung Cancer. As of june 14, 2017, 21 patients were enrolled in dose-escalation cohort (DAC).